Lexicon Pharmaceuticals Inc LXRX
Find similar stocks with Morningstar Investor.
Morningstar analysts do not currently cover LXRX, but with our powerful screener, you can find
stocks in the same sector,industry, or style and filter on our unbiased ratings and valuation metrics.
News
-
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
-
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer
-
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
-
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences
-
New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration
-
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista
-
Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio
-
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists
Trading Information
- Previous Close Price
- $1.61
- Day Range
- $1.62–1.71
- 52-Week Range
- $0.92–3.73
- Bid/Ask
- $1.58 / $1.68
- Market Cap
- $610.92 Mil
- Volume/Avg
- 294 / 2.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 121.48
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.30%
Company Profile
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 285
- Website
- https://www.lexpharma.com
Comparables
Valuation
|
Metric
|
LXRX
|
TRVI
|
SUPN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 110.05 |
Price/Book Value | 2.55 | 3.31 | 1.84 |
Price/Sales | 121.48 | — | 2.78 |
Price/Cash Flow | — | — | 15.62 |
Price/Earnings
LXRX
TRVI
SUPN
Financial Strength
|
Metric
|
LXRX
|
TRVI
|
SUPN
|
|---|---|---|---|
Quick Ratio | 11.21 | 10.29 | 1.62 |
Current Ratio | 11.51 | 10.68 | 1.91 |
Interest Coverage | −11.96 | −4,780.89 | — |
Quick Ratio
LXRX
TRVI
SUPN
Profitability
|
Metric
|
LXRX
|
TRVI
|
SUPN
|
|---|---|---|---|
Return on Assets (Normalized) | −57.60% | −40.88% | 2.90% |
Return on Equity (Normalized) | −98.03% | −44.19% | 4.05% |
Return on Invested Capital (Normalized) | −61.39% | −48.62% | 2.99% |
Return on Assets
LXRX
TRVI
SUPN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Ywtzctmr | Cgdwm | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cbsbhdwcj | Dffxlf | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Sgbssgfnz | Lnvdwk | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ycqychqpk | Nkrkrc | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Nmkmylvf | Ydyb | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Xcvjvlzf | Wgkx | $29.2 Bil | |||
| Moderna Inc
MRNA
| Nxdvngmf | Fkc | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Lfdhmjm | Wxhrq | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pkvpvxkp | Rrhsn | $13.2 Bil | |||
| Incyte Corp
INCY
| Xkhwdwzdd | Rrkxdq | $13.0 Bil |
United States